<DOC>
	<DOCNO>NCT01052051</DOCNO>
	<brief_summary>To determine effect increase serum 25 ( OH ) D prevailing level vitamin D3 supplementation , maintain adequate calcium intake , incidence all-type cancer population sample healthy postmenopausal woman .</brief_summary>
	<brief_title>Clinical Trial Vitamin D3 Reduce Cancer Risk Postmenopausal Women</brief_title>
	<detailed_description>Hypotheses : Primary : Increasing serum 25 ( OH ) D prevailing level vitamin D3 supplementation , maintain adequate calcium intake , significantly decrease incidence all-type cancer population sample healthy postmenopausal woman . Secondary : 1 . Increasing serum 25 ( OH ) D prevailing level significantly decrease incidence specific cancer : breast , lung , colon , myeloma , leukemia , lymphoma . 2 . Increasing serum 25OHD prevailing level significantly decrease incidence disorder , specifically hypertension , cardiovascular disease , osteoarthritis , colonic adenoma , diabetes , upper respiratory infection fall . Specific Aims : 1 . Determine effect supplementation vitamin D3 incidence type cancer combine . 2 . Determine nested-case control study association serum 25OHD collect randomization end year one study risk cancer four year . 3 . Sample randomly population healthy independently-living postmenopausal woman 55 year old twelve adjacent rural county Nebraska . 4 . Enroll random sample 2300 woman intervention study , assign randomly one two treatment group : 1 ) vitamin D3 ( 2000 IU/d ) calcium ( 1500 mg/d ) , 2 ) vitamin D3 placebo calcium placebo , follow study participant four year . 5 . Collect store blood serum white blood cell every participant test genetic marker intervention find effective decreasing incidence cancer . Markers select determined state science time analysis . 6 . Determine effect supplementation calcium vitamin D3 incidence specific cancer : breast , lung , colon , myeloma , leukemia , lymphoma . 7 . Determine effect supplementation incidence disorder , specifically hypertension , cardiovascular disease , osteoarthritis , colonic adenoma , diabetes , upper respiratory infection , fracture , fall .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Age : ≥ 55 year Last menstrual period ( LMP ) : ≥ 4 year Good general health Willingness participate 4 year long study Able give inform consent Able live independently travel Fremont Area Medical Center ( FAMC ) study visit History cancer except Superficial basal squamous cell carcinoma skin Other malignancy treat curatively 10 year ago History renal calculus chronic kidney disease History sarcoidosis History tuberculosis Participation previous Creighton cancer prevention study MiniMental Status Exam ( MMSE ) score ≤ 23 . Use MMSE concern person 's cognitive ability ability give fully inform consent study . Concerns may relate person 's lack orientation person , place , time ; language difficulty ( inability structure simple , complete sentence ) ; short term memory . The Hartford Institute Geriatric Nursing recommend score 23 low indicates cognitive impairment . ( Accessed www.harforddign.org ) . See appendix .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>